<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01438437</url>
  </required_header>
  <id_info>
    <org_study_id>23-16/11/2001</org_study_id>
    <nct_id>NCT01438437</nct_id>
  </id_info>
  <brief_title>Trial of Ablation of Small Hepatocellular Carcinomas in Patients of Cirrhosis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>All India Institute of Medical Sciences, New Delhi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>All India Institute of Medical Sciences, New Delhi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of Radiofrequency ablation (RFA) and&#xD;
      percutaneous acetic acid ablation (PAI) in the management of small hepatocellular carcinoma&#xD;
      (HCC) in patients of cirrhosis of liver.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Setting The study would be conducted at the All India Institute of Medical Sciences, New&#xD;
      Delhi, a tertiary care teaching hospital, in the departments of Gastroenetrology and&#xD;
      Radiodiagnosis.&#xD;
&#xD;
      Sample size Taking RFA as a standard procedure with an estimated success rate of 95%, a&#xD;
      sample size of minimum 27 for each arm is required to detect an equivalence difference of&#xD;
      10%, assuming that PAI has a success rate of 85%. This sample size is expected to provide a&#xD;
      power of 80%.&#xD;
&#xD;
      Randomization&#xD;
&#xD;
        -  Stratified randomization of Child A and B will be done.&#xD;
&#xD;
        -  Randomization into A (Acetic acid) and B (Radiofrequency ablation) will be done.&#xD;
&#xD;
      Diagnostic criteria&#xD;
&#xD;
        -  Cirrhosis of liver- Diagnosis will be founded on the basis of clinical, biochemical,&#xD;
           imaging and endoscopy findings.&#xD;
&#xD;
      Hepatocellular carcinoma- when any one of the following is present&#xD;
&#xD;
        1. Two imaging modalities (dual phase CT (DPCT)/ contrast enhanced Magnetic Resonance&#xD;
           Imaging (MRI)) showing arterialization of the hepatic mass&#xD;
&#xD;
        2. AFP more than 400ng/ml along with arterialisation on one imaging modality (DPCT/&#xD;
           contrast enhanced MRI)&#xD;
&#xD;
        3. Fine needle aspiration cytology (FNAC)&#xD;
&#xD;
      Definitions&#xD;
&#xD;
        1. Local recurrence : When the Triple phase CT shows-&#xD;
&#xD;
             -  An area of nodular enhancement that abuts or surrounds the ablation defect or&#xD;
                protrudes into the low attenuating necrotic tissue (may sometimes be seen only on&#xD;
                arterial phase of CT)&#xD;
&#xD;
             -  Recurrent soft tissue causing distortion of the otherwise smooth interphase with&#xD;
                the adjoining liver parenchyma.&#xD;
&#xD;
        2. Fresh lesion- When a new lesion is seen in the liver at a site other than the primary&#xD;
           site of the treated lesion with normal liver parenchyma intervening in between will be&#xD;
           considered as a fresh lesion.&#xD;
&#xD;
        3. Residual disease or incomplete ablation When the follow up Triple phase CT shows-&#xD;
&#xD;
             -  Residual nodular enhancement that abuts or surrounds the low attenuating ablation&#xD;
                defect or protrudes into the low attenuating necrotic tissue (may sometimes be seen&#xD;
                only on arterial phase of CT)&#xD;
&#xD;
             -  Residual soft tissue causing distortion of the otherwise smooth interphase with the&#xD;
                adjoining liver parenchyma.&#xD;
&#xD;
             -  Concenteric hyperemia around the low attenuating defect showing area of focal&#xD;
                nodularity or asymmetric thickness.&#xD;
&#xD;
        4. End point of ablation When the Triple phase CT shows-&#xD;
&#xD;
             -  A homogenous, well defined, uniformly low attenuating defect larger than the&#xD;
                pretreatment size.&#xD;
&#xD;
             -  No residual soft tissue seen within or at the periphery of the low attenuating&#xD;
                defect&#xD;
&#xD;
             -  Concentric hyperemia around the low attenuating defect of uniform thickness with no&#xD;
                focal nodularity.&#xD;
&#xD;
      Follow up&#xD;
&#xD;
        1. Clinical follow up&#xD;
&#xD;
             -  All patients would be followed up in the Liver clinic monthly unless their clinical&#xD;
                condition warrants earlier follow up&#xD;
&#xD;
             -  Liver function tests/ complete blood count would also be done at each visit and&#xD;
                Alfafetoprotein (AFP) every six months&#xD;
&#xD;
             -  Patient tolerance, child's status would be estimated.&#xD;
&#xD;
        2. Imaging follow up&#xD;
&#xD;
             -  At one month, a dual phase CT would be done to ascertain the local response to&#xD;
                therapy and the need to repeat the procedure. After achieving the end point after&#xD;
                ablation (PAI and RFA, the DPCT would be done at 3 and 6 monthly intervals.&#xD;
&#xD;
      Duration of follow up - Since more than 80% recurrence occurs in 2 years therefore the&#xD;
      duration of follow up would be 2 years after ablation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2001</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local tumor response</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with complications</measure>
    <time_frame>2 years</time_frame>
    <description>Number of patients developing any complications during and after procedure will be noted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Child status at 1 year</measure>
    <time_frame>2 years</time_frame>
    <description>Child status is calculated from the following 5 parameters&#xD;
Bilirubin &lt; 2: 1, 2-3: 2 and &gt; 3 : 3 points&#xD;
Albumin: &gt; 3.5: 1, 2.8-3.5 : 2 and &lt;2.8: 3 points&#xD;
Prothrombin time( seconds over control): 1-3: 1, 4-6: 2 and &gt; 6: 3&#xD;
Encephalopathy: None: 1, (grade 1 and 2): 2 and (grade 3 and 4): 3&#xD;
Ascites: Absent: 1, slight: 2 and moderate: 3&#xD;
Child A: score 5-6, Child B: 7-9 and Child C: 10 or more</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Percutaneous acetic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiofrequency ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PAI</intervention_name>
    <description>Under local anaesthesia, taking proper aseptic precautions, 40% acetic acid (total dose not exceeding 3 times the diameter of the mass, (not more than 2ml in one sitting), will be injected into the mass through the percutaneous route</description>
    <arm_group_label>Percutaneous acetic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>RFA</intervention_name>
    <description>Under aseptic conditions and local anesthesia, the needle electrode would be introduced percutaneously into the tumor under ultrasound guidance.</description>
    <arm_group_label>Radiofrequency ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Child's A or B cirrhosis with liver mass.&#xD;
&#xD;
          -  Number of liver masses not more than 5 and the size of each &lt;5cm in diameter.&#xD;
&#xD;
          -  No extrahepatic disease.&#xD;
&#xD;
          -  Absence of malignant portal vein thrombosis.&#xD;
&#xD;
          -  Platelet count more than 70,000/mm3&#xD;
&#xD;
          -  Prothrombin time more than 50%.&#xD;
&#xD;
          -  Written consent of patient.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Childs'C cirrhosis with liver mass.&#xD;
&#xD;
          -  Liver mass &gt;5cm in diameter.&#xD;
&#xD;
          -  Number of liver masses more than 3&#xD;
&#xD;
          -  Peripherally located masses with no hepatic parenchyma around&#xD;
&#xD;
          -  Liver mass not discernable on ultrasound.&#xD;
&#xD;
          -  Extra hepatic disease like RP adenopathy, distant metastasis.&#xD;
&#xD;
          -  Coagulation disorders.&#xD;
&#xD;
          -  Unwilling patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Subrat K Acharya, DM</last_name>
    <phone>01126594934</phone>
    <email>subratacharya2004@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AIIMS</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Subrat K Acharya, DM</last_name>
      <phone>911126594934</phone>
      <email>subratacharya2004@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>September 14, 2011</study_first_submitted>
  <study_first_submitted_qc>September 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2011</study_first_posted>
  <last_update_submitted>July 12, 2012</last_update_submitted>
  <last_update_submitted_qc>July 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>All India Institute of Medical Sciences, New Delhi</investigator_affiliation>
    <investigator_full_name>Subrat Kumar Acharya</investigator_full_name>
    <investigator_title>Proffessor and Head</investigator_title>
  </responsible_party>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>Radiofrequency ablation</keyword>
  <keyword>Percutaneous acetic acid ablation</keyword>
  <keyword>Tumour response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

